Results 171 to 180 of about 772,552 (212)

Colestipol in familial type II hyperlipoproteinemia: A three‐year trial

Clinical Pharmacology & Therapeutics, 1976
Colestipol. a new bile acid sequestrant polymer. has been shown to lower the serum cholesterol level more than 30% in 13 patients with familial type 11 hyperlipoproteinemia. Placebo for 6 wk was followed by colestipol for periods up to 36 mo. A slight but not significant increase of serum triglyceride concentrations was observed during the first 18 mo.
C, Harvengt, J P, Desager
openaire   +2 more sources

Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia

The American Journal of Cardiology, 1986
Patients with low-density lipoprotein (LDL) concentrations in the top 10th percentile of the population (type II hyperlipoproteinemia [HLP]) are at increased risk for premature cardiovascular disease; however, the incidence of myocardial infarction and death can be decreased by LDL cholesterol reduction.
Jeffrey M. Hoeg, Martha B. Maher, Loren A. Zech, Kent R. Bailey, Richard E. Gregg, Karl J. Lackner, Silvia S. Fojo, Michael A. Anchors, Marina Bojanovski, Dennis L. Sprecher, H.Bryan Brewer   +10 more
openaire   +2 more sources

[Sitosterol in familial hyperlipoproteinemia type II. A randomized double-blind cross-over study].

Deutsche Medizinische Wochenschrift, 1976
P. Oster, G. Schlierf, C. Heuck, H. Greten, U. Gundert-Remy, W. Haase, G. Klose, A. Nothelfer, H. Raetzer, B. Schellenberg, H. Schmidt‐Gayk   +10 more
semanticscholar   +1 more source

LDL- and agonist-induced Ca(2+)-mobilization in platelets of healthy subjects and in patients with familial hyperlipoproteinemia type II.

Thrombosis Research, 1991
V. Bochkov, T. Rozhkova, Matchin YuG, A. Lyakishev, N. Bochkova, Borisova YuL, V. Kukharchuk, V. Tkachuk   +7 more
semanticscholar   +1 more source

Prevalence and Distribution of Femoral Atheromas in Human Hyperlipoproteinemia, Type II and IV

, 1974
D. Blankenhorn, R. Barndt, D. Crawford, R. Selzer, E. Beckenbach   +4 more
semanticscholar   +1 more source

[Familial IgM deficiency and type II hyperlipoproteinemia].

Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1978
It is reported on the common appearance of a hyperlipoproteinaemia type II after Fredrickson and of a selective insufficiency of IgM in a family. The two generations of a family which have been observed since three years show these disturbances in a 42-year-old patient and all his four children.
H, Storch, B, Kuklinski, H, Schwenke
openaire   +1 more source

Cholestyramine in Type II Hyperlipoproteinemia

Annals of Internal Medicine, 1973
R I, Levy, D S, Fredrickson, N J, Stone, D W, Bilheimer, W V, Brown, C J, Glueck, A M, Gotto, P N, Herbert, P O, Kwiterovich, T, Langer, J, LaRosa, S E, Lux, A K, Rider, R S, Shulman, H R, Sloan   +14 more
openaire   +2 more sources

Influence of fenofibrate on blood rheology in type II hyperlipoproteinemia

, 2016
H. Arntz, I. Gogolwske, J. Heitz, J. Schäfer, R. Schröder   +4 more
semanticscholar   +1 more source

Neonatal familial type II hyperlipoproteinemia: cord blood cholesterol in 1800 births.

Metabolism: Clinical and Experimental, 1971
C. J. Glueck, Frank Heckman, Michael Schoenfeld, P. Steiner, W. Pearce   +4 more
semanticscholar   +1 more source

[Evaluation of the pseudocholinesterase activity in hyperlipoproteinemia type II and type IV].

Bollettino della Societa italiana di biologia sperimentale, 1983
Authors have evaluated pseudocholinesterase activity in patients with type IIa and type IV hyperlipoproteinemia. Significative correlation has been found between PCE and C in type IV hyperlipoproteinemia. Authors suggest PCE activity can be proposed as useful biochemical marker of hyperlipoproteinemia.
M R, Averna, G, Montalto, G B, Rini, G, Di Fede, M, Labisi, G, Marino, A, Notarbartolo   +6 more
openaire   +1 more source